ScandiDos (SDOS.ST) Stock Analysis & AI Equity Report
ScandiDos (SDOS.ST) overview
ScandiDos (SDOS.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, ScandiDos reported revenue of SEK 54.2m and operating profit of SEK -2.7m; the year-end share price was 0.98 SEK and market capitalisation was SEK 55.9m. ScandiDos is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ScandiDos's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About ScandiDos
ScandiDos develops and sells quality assurance solutions for radiation therapy, centered on the Delta4 product family of measurement phantoms, software and motion platforms. Its systems help hospitals and clinics verify dose delivery, machine performance and treatment accuracy for advanced cancer radiotherapy. The company also provides related support and service through an international sales network.
Generate the ScandiDos report
ScandiDos is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ScandiDos and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.